NT_1170x120_1-11-18

PBM industry

NCPA CEO urges federal action on PBMs

NCPA CEO urges federal action on PBMs

 At a health subcommittee hearing of the U.S. House of Representatives Energy & Commerce Committee, B. Douglas Hoey, CEO of the National Community Pharmacists Association (NCPA), called for legislative and regulatory action on pharmacy benefit manager (PBM) business practices to help rein in prescription drug costs. The hearing, titled “Examining the Drug Supply Chain”

Congress reintroduces DIR fee legislation

Congress reintroduces DIR fee legislation

WASHINGTON — Reps. Morgan Griffith (R., Va.) and Peter Welch (D., Vt.) have reintroduced the Improving Transparency and Accuracy in Medicare Part D Spending Act (H.R. 1038), which community pharmacies say would squelch a growing burden: retroactive direct and indirect remuneration (DIR) fees. The bill, introduced Wednesday in the House of Representatives, would ban the application

NCPA to Congress: More scrutiny of PBMs needed

NCPA to Congress: More scrutiny of PBMs needed

ALEXANDRIA, Va. — In comments to Congress, the National Community Pharmacists Association called for more oversight of pharmacy benefit management (PBM) companies. NCPA said payers, pharmacy patients and pharmacists could see “tangible benefits” from increased transparency into PBM business practices and potential conflicts of interests. The association submitted its comments to the House Committee on